Zepzelca

Active Ingredient(s): Lurbinectedin
FDA Approved: * June 15, 2020
Pharm Company: * JAZZ
Category: Cancer

Lurbinectedin, sold under the brand name Zepzelca, is a medication for the treatment of adults with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.[2][3][4] The most common side effects include leukopenia, lymphopenia, fatigue, anemia, neutropenia, increased creatinine, increased alanine aminotransferase, increased glucose, thrombocytopenia, nausea, decreased appetite, musculoskeletal pa... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Zepzelca .5 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 68727-712
Labeler:
Jazz Pharmaceuticals, Inc.